261. A Single-Center Case Series of Methicillin-Resistant S. aureus Bacteremia with Elevated Minimal Inhibitory Concentrations to Vancomycin

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is a serious nosocomial pathogen, and is listed as a “High Priority Pathogen” by the WHO due to concerns of antimicrobial resistance and lack of novel therapeutics. Even in vancomycin-susceptible MRSA, increased rates of treatment failure occur in the setting of an increased minimum inhibitory concentration (MIC) to vancomycin, which is considered the gold-standard of therapy. We performed a case series of 25 patients infected with MRSA with an elevated MIC to vancomycin. Additionally, we describe the use of combination therapy with beta-lactams for the management of these highly complex cases. METHODS: We conducted a retrospective case series of 25 patients hospitalized at MSH between 8/2014–5/2019 who were treated for MRSA bacteremia where the isolate had an MIC ≥ 2. Data was centralized into the REDCap program. Clonal typing of bacteria and analysis of clinical features were performed in SAS and R. RESULTS: In total, 25 patients developed MRSA bacteremia with a vancomycin MIC ≥ 2. The majority of cases involved infection from vascular access, arteriovenous fistula/graft, and septic joint/osteomyelitis. All 25 patients were initially treated with vancomycin, with modification of therapy varying widely depending on clinician. The most common vancomycin-alternative was daptomycin (14/25 patients, alone and in combination). Combination therapy with vancomycin or daptomycin and a beta-lactam was used in 9 cases (36% of cases). Average number of days to clearance was 18.3 (range 1–69 days). Univariate and multivariate analyses revealed significant correlation MRSA bacteremia with vancomycin MIC ≥ 2 and admission from a nursing home or skilled nursing facility (p=0.02), history of MRSA colonization (p=0.006), and persistent bacteremia (bacteremia >7 days)(p< .0.001). CONCLUSION: With few novel therapeutics under development, management of MRSA bacteremia with a rising MIC to vancomycin is a clinical challenge for practitioners. In our case series we found that treatment is largely patient and practitioner-dependent, and far from standardized. Further definition of the clinical risk factors for development and novel therapeutic strategies will enable understanding of how to best manage these challenging infections. DISCLOSURES: All Authors: No reported disclosures